High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19 - 28/04/21
Highlights |
• | Reactivations of EBV, CMV and HHV-6 are frequent in severe COVID-19. |
• | EBV reactivation is associated with longer ICU length-of-stay. |
• | EBV reactivation occurs early after ICU admission. |
• | CMV reactivation occurs later after ICU admission and may require anti-CMV treatment. |
Abstract |
Background |
Systemic reactivation of herpesviruses may occur in intensive care unit (ICU) patients and is associated with morbidity and mortality. Data on severe Coronavirus disease-19 (COVID-19) and concomitant reactivation of herpesviruses are lacking.
Methods |
We selected patients admitted to ICU for confirmed COVID-19 who underwent systematic testing for Epstein–Barr virus (EBV), cytomegalovirus (CMV) and human-herpes virus-6 (HHV-6) DNAemia while in the ICU. We retrospectively analysed frequency, timing, duration and co-occurrence of viral DNAemia.
Results |
Thirty-four patients were included. Viremia with EBV, CMV, and HHV-6 was detected in 28 (82%), 5 (15%), and 7 (22%) patients, respectively. EBV reactivation occurred early after ICU admission and was associated with longer ICU length-of-stay.
Conclusions |
While in the ICU, critically ill patients with COVID-19 are prone to develop reactivations due to various types of herpesviruses.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, Cytomegalovirus, Epstein–Barr virus
Plan
Vol 51 - N° 3
P. 296-299 - mai 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.